These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 29574395)

  • 1. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
    Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
    Shen Y; Chen J; Liu Y; Wu D
    Chemotherapy; 2014; 60(5-6):368-74. PubMed ID: 26496511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
    Seligson ND; Hobbs ALV; Leonard JM; Mills EL; Evans AG; Goorha S
    Ann Pharmacother; 2018 May; 52(5):439-445. PubMed ID: 29241342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
    Wiedower E; Jamy O; Martin MG
    Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.
    Woelich SK; Braun JT; Schoen MW; Ramlal R; Freter CE; Petruska PJ; Lionberger JM
    Anticancer Res; 2017 Feb; 37(2):713-717. PubMed ID: 28179321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
    Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
    Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
    Mayer K; Hahn-Ast C; Schwab K; Schmidt-Wolf IGH; Brossart P; Glasmacher A; von Lilienfeld-Toal M
    Eur J Haematol; 2020 Jun; 104(6):538-545. PubMed ID: 32049382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
    Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
    Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
    Pluta A; Robak T; Wrzesien-Kus A; Katarzyna Budziszewska B; Sulek K; Wawrzyniak E; Czemerska M; Zwolinska M; Golos A; Holowiecka-Goral A; Kyrcz-Krzemien S; Piszcz J; Kloczko J; Mordak-Domagala M; Lange A; Razny M; Madry K; Wiktor-Jedrzejczak W; Grosicki S; Butrym A; Kuliczkowski K; Warzocha K; Holowiecki J; Giebel S; Szydlo R; Wierzbowska A
    Am J Hematol; 2017 Apr; 92(4):359-366. PubMed ID: 28103640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
    Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
    Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
    Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
    Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
    Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
    Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
    Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
    Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
    Qasrawi A; Bahaj W; Qasrawi L; Abughanimeh O; Foxworth J; Gaur R
    Ann Hematol; 2019 Mar; 98(3):561-579. PubMed ID: 30470874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
    Fridle C; Medinger M; Wilk MC; Seipel K; Passweg J; Manz MG; Pabst T
    Leuk Lymphoma; 2017 May; 58(5):1068-1075. PubMed ID: 27735213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
    Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
    Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
    Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.